Moon phase today: What the moon will look like on June 25 2025
Looking up at the sky and wondering where the moon is? Today's lack of beautiful moonlight isn't a mystery; it's to do with where we are in the lunar cycle. Intrigued? Keep reading.
The lunar cycle is a series of eight phases of the moon's visibility, based on how much light the sun shines on it. The whole cycle takes about 29.5 days, according to NASA, and these different phases happen as the Sun lights up various parts of the moon whilst it orbits Earth.
Here's what the moon is doing today, June 25, 2025.
As of Wednesday, June 25, the moon phase is New Moon. In this phase, you can't see the moon at all. 0%, to be precise (according to NASA's Daily Moon Observation).
Today also marks day 0 of the lunar cycle. During this phase, the lit up side of the moon is facing the Sun rather than Earth. According to NASA, the Moon usually doesn't pass directly between Earth and the Sun during this phase because its orbit is slightly tilted. From our view on Earth, it just appears to pass near the Sun.
As you would expect, there's no chance of spotting anything on the moon's surface tonight, even if you have a telescope.
June's full moon was on June 11. The next full moon will be on July 10.
We've now reached day 0 of the 29.5-day lunar cycle. This is a cycle, NASA tells us, caused by the angles between the sun, moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. So, sometimes it looks full, sometimes half, and sometimes not there at all. There are eight main moon phases, and they follow a repeating cycle:
New Moon - The moon is between Earth and the sun, so the side we see is dark (in other words, it's invisible to the eye).
Waxing Crescent - A small sliver of light appears on the right side (Northern Hemisphere).
First Quarter - Half of the moon is lit on the right side. It looks like a half-moon.
Waxing Gibbous - More than half is lit up, but it's not quite full yet.
Full Moon - The whole face of the moon is illuminated and fully visible.
Waning Gibbous - The moon starts losing light on the right side.
Last Quarter (or Third Quarter) - Another half-moon, but now the left side is lit.
Waning Crescent - A thin sliver of light remains on the left side before going dark again.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Pensacola area will see frequent showers, thunderstorms into early July
A slow-moving weather pattern moving north from South Florida will bring more instability to the Pensacola area over the weekend as it meets with a dip in the jet stream over the southeastern United States. The wet weather pattern is likely to stick around through the end of June and into early July, according to AccuWeather. Leftover energy from Wednesday's round of storms continues to linger above the Pensacola area and could be used to spawn some strong isolated thunderstorms on Thursday, according to the National Weather Service office in Mobile, Alabama. Any storm that forms on Thursday will be weaker than the storms that hit earlier this week, which created strong wind gusts on Pensacola Beach and one-inch hail in Santa Rosa County. Downburst winds are still the primary threat on Thursday, and small hail is still possible. The Pensacola area escaped Wednesday's storms relatively unscathed. One storm report noted one-inch hail near Airport Road in Milton, but no damage or injuries were reported. There were around 19 wind-related storm reports across the Florida Panhandle, including one person who was injured after a gust of wind capsized a boat in Grand Lagoon. Most of the reports involved downed trees and power lines. Wind gusts up to 61 mph along the Gulf Coast. An abundance of moisture and complex weather conditions over the southeastern U.S. and South Florida is setting up an environment for daily afternoon and evening thunderstorms through the end of June. A slight dip in the jet stream over the southeastern U.S. will funnel moisture in from the Gulf over the next week. Meanwhile, a closed upper low over southern Florida is making its way north toward the same area. Current daily MLCAPE values, which measure the potential energy for storms, have risen into the 2,500-3,500 J/kg range, which indicates a strong updraft potential that could sustain severe thunderstorms. Daily DCAPE values have been measured between 900-1,200 J/kg, which means there is a heightened risk of damaging downburst winds. Storms will bring the risk of heavy rainfall, downburst winds and even coastal waterspouts from convection in the Gulf. This article originally appeared on Pensacola News Journal: Pensacola area to see frequent showers, thunderstorms into early July
Medscape
an hour ago
- Medscape
Sclerosing Mesenteritis: Update on Rare GI Disease
The American Gastroenterological Association (AGA) has issued an updated pragmatic review on sclerosing mesenteritis (SM). Published in Clinical Gastroenterology and Hepatology, the update evaluates available evidence for diagnosis and treatment and examines opportunities for future research in SM, previously known by such names as misty mesentery, mesenteric panniculitis, and inflammatory pseudotumor. Led by Mark T. Worthington, MD, a professor of medicine in the Division of Gastroenterology and Hepatology at the University of Virginia in Charlottesville, Virginia, an expert AGA panel described SM as an uncommon benign idiopathic autoimmune disease of the mesenteric fat. Although of poorly understood etiology, gastroenterologists need to be prepared to diagnose it. 'CT radiologists increasingly are reporting SM and related lesions, such as misty mesentery,' Worthington told Medscape Medical News . 'We are also seeing new SM cases caused by immune checkpoint inhibitors in cancer treatment, and the oncologists ask us to manage this because it interferes with the treatment of the underlying malignancy. Those are often readily treated because we catch them so early.' Metabolic syndrome and associated conditions increase the risk for SM, as does aging. The recent changes are intended to help clinicians predict disease activity and the need for other testing or treatment. 'For instance, most cases are indolent and do not require aggressive treatment — often no treatment at all — but for those that are aggressive, we want the clinician to be able to identify those and make sure the treatment is appropriate. The aggressive cases may warrant tertiary referral,' Worthington said. 'A secondary cancer is a possibility in this condition, so drawing from the SM radiology studies, we try to help the clinician decide who needs other testing, such as PET-CT or biopsy, and who can be monitored.' As many as 60% of cases are asymptomatic, requiring no treatment. Abdominal pain is the most frequent symptom and its location on clinical examination should correspond to the SM lesion on imaging. Treatment involves anti-inflammatory medications tailored to disease severity and clinical response. No biopsy is not necessary if the lesion meets three of the five CT criteria reported by B. Coulier and has no features of more aggressive disease or malignancy. Although some have suggested that SM may be a paraneoplastic syndrome, current evidence does not support this. SM needs to be differentiated from other diagnoses such as non-Hodgkin's lymphoma, peritoneal carcinomatosis, and mesenteric fibromatosis. 'There are now CT guidelines for who actually has SM, who needs a biopsy or a PET-CT to rule-out malignancy, and who doesn't,' said Worthington. 'Radiologists do not always use the Coulier criteria for diagnosis, but often they will with encouragement. From this review, a GI clinician should be able to identify SM on CT.' Epidemiologically, retrospective CT studies have reported a frequency of 0.6%-1.1%, the panelists noted. And while demographic data are limited, a large early case series reported that SM patients had a mean age of 55 years and more likely to be men and of White race. Patients with SM do not have a higher prevalence of autoimmunity in general, but may have increased rates of metabolic syndrome, obesity, coronary artery disease, and urolithiasis, the panelists noted. The update allows room for differences in clinical judgment. 'For instance, a longer or more frequent CT surveillance interval can be justified depending on the patient's findings, and no one should feel locked in by these recommendations,' Worthington said. Medical Therapy Although there is no surgical cure, pharmacologic options are many. These include prednisone, tamoxifen, colchicine, azathioprine, thalidomide, cyclophosphamide, and methotrexate, as well as the biologics rituximab, infliximab and ustekinumab. Current corticosteroid-based therapies often require months to achieve a clinical response, however. Bowel obstruction is managed nonoperatively when feasible, but medically refractory disease may require surgical bypass. Offering his perspective on the guidance but not involved in its formulation, Gastroenterologist Stephen B. Hanauer, MD, a professor of medicine at Northwestern Medicine in Chicago, said, 'The most useful component of the practical review is the algorithm for diagnosis and determination when biopsy or follow-up imaging is reasonable in the absence of evidence.' He stressed that the recommendations are pragmatic rather than evidence-based 'as there are no controlled trials and the presentation is heterogeneous.' Hanauer added that none of the recommended treatments have been shown to impact reduction on imaging. 'Hence, all of the treatments are empiric without biological or imaging endpoints.' In his experience, patients with inflammatory features are the best candidates for immune-directed therapies as reduction in inflammatory markers is a potential endpoint, although no therapies have demonstrated an effect on imaging or progression. 'As an IBD doctor, I favor steroids and azathioprine or anti-TNF directed therapy, but again, there is no evidence beyond reports of symptomatic improvement.' Worthington and colleagues agreed that treatment protocols have developed empirically. 'Future investigation for symptomatic SM should focus on the nature of the inflammatory response, including causative cytokines and other proinflammatory mediators, the goal being targeted therapy with fewer side effects and a more rapid clinical response,' they wrote. Currently, said Worthington, the biggest gaps remain in treatment. 'Even the best studies are small and anecdotal, and we do not know the cytokine or other proinflammatory mediators.' In other comments, Gastroenterologist Eli D. Ehrenpreis, MD, research director, Internal Medicine Residency, at Advocate Lutheran General Hospital in Park Ridge, Illinois, and not involved in the update, found it fell short in several ways, including nomenclature. 'The appropriate term for this condition is mesenteric panniculitis, meaning inflammation of the mesenteric fat, seen histologically on biopsy. The term sclerosing mesenteritis introduces the idea of fibrosis, which is seen in a smaller number of patients, not all,' he told Medscape Medical News . Ehrenpreis also took issue with the inclusion of the cancer drug tamoxifen as the most common treatment used. 'Mesenteric panniculitis, when it does not represent a malignancy, is a benign disease,' he said. 'However, many patients on tamoxifen will experience hormone-related adverse effects such as breast tenderness and hot flashes.' He noted the drug has an FDA Black Box warning for uterine malignancies, pulmonary embolism, and other thromboembolic events, including stroke. Another significant gap, in his view, is the lack of recognition of the psychological effects on patients of the diagnosis. According to Ehrenpreis, more prospective analyses of treatments are needed with objective measures of success including symptom scoring and laboratory testing with erythrocyte sedimentation rate and C-reactive protein. 'And as with many rare diseases, a better understanding of the psychological effects of having a poorly understood disease and management of this challenge is vital to the comprehensive care of the patient with mesenteric panniculitis.' This guidance was supported by the AGA. Worthington reported renumeration from TriCity Surgery Center, Prescott, Ariz. The coauthor Wolf has received renumeration from AbbVie, Align Technology, Alnylam Pharmaceuticals, CVS Health ORP, Dexcom, Exact Sciences, HCA Healthcare, Johnson & Johnson, Eli Lilly, McKesson, Moderna, Regeneron Pharmaceuticals, Sarepta Therapeutics, Seagen, Stryker, and Thermo Fisher Scientific. Crockett has served as a consultant for IngenioRx. Pardi has served as a consultant for Boehringer Ingelheim and received research support from Atlantic, ExeGI Pharma, Rise Therapeutics, Janssen, Pfizer, Seres, Applied Molecular Transport, Takeda Pharmaceuticals, and Vedanta Biosciences. Hanauer and Ehrenpreis had no conflicts of interest relevant to their comments.
Yahoo
an hour ago
- Yahoo
Wearing a Weighted Vest May Help Maintain Weight Loss 2 Years After Dieting, New Study Finds
We all know that losing weight is one thing, but keeping it off? That's the real mountain. Most of us have felt that frustrating boomerang effect after months of hard graft. In fact, many studies indicate that long-term weight loss maintenance is particularly difficult to achieve. But what if there was a way to support the metabolism and increase the chances of keeping the weight off? That's exactly what a group of researchers set out to explore, not with obscure diets or another app, but with something surprisingly simple: a weighted vest. They hypothesised that your body has a kind of internal weight sensing system (called the gravitostat), and if you can keep it 'tricked' into feeling heavier, you might avoid the usual metabolic slowdown that leads to weight regain. While this is a very new area of study, and more research is needed, here's what the researchers found, and what it could mean for the way we think about sustainable weight loss. The researchers of the pilot study, published in the International Journal of Obesity, aimed to explore whether wearing a weighted vest during a weight loss programme could help older adults with obesity maintain weight loss over the long term, possibly by preventing the usual drop in metabolism that leads to weight regain. The study methods included: 18 older adults with obesity and osteoarthritis took part in a 6-month weight loss programme using meal replacements and dietary counselling. Half the group also wore a weighted vest up to 10 hours a day during this time, with the vest weight gradually increased to match the amount of weight they lost. No participants wore the vest after the 6 months, but researchers followed up 24 months after the start of the study to measure weight and metabolic rate. Both groups lost a similar amount of weight during the first 6 months (about 10-11 kg). At 24 months, the vest group had regained only half of their lost weight, while the non-vest group regained all of it. The vest group also showed much less of a drop in resting metabolic rate, which may have helped prevent the weight regain. Wearing a weighted vest during dieting may help the body feel heavier, activating a system called the gravitostat that helps regulate weight and metabolism. This could be a promising tool for improving long-term weight loss success, especially for older adults or those unable to exercise. But before we get too excited, larger studies are needed before this becomes a general recommendation for people trying to lose weight. The study was small, plus, while wearing a vest for a workout or a walk is feasible, for 10 hours a day is a little bit of a stretch. You may find it more comfortable to include a weighted vest in your workouts, or for your walks. Another study has shown that doing so can increase your energy burn by as much as 40%. However, if you're curious to find out more about what it's like to wear a weighted vest all day, our writer did exactly that, and detailed his experience. You can read all about it here: You Might Also Like The 23 Best Foods to Build Muscle 10 of the Best Waterproof Boots to Buy in 2019 6 Ways to Improve Your Mental Health
